140 related articles for article (PubMed ID: 35727899)
1. New biomarker paves the way for a clinical trial for neurodegeneration in Langerhans cell histiocytosis.
Shioda Y; Sakamoto K; Morimoto A
Br J Haematol; 2022 Aug; 198(4):623-624. PubMed ID: 35727899
[TBL] [Abstract][Full Text] [Related]
2. Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma.
Sveijer M; von Bahr Greenwood T; Jädersten M; Kvedaraite E; Zetterberg H; Blennow K; Lourda M; Gavhed D; Henter JI
Br J Haematol; 2022 Aug; 198(4):721-728. PubMed ID: 35582775
[TBL] [Abstract][Full Text] [Related]
3. Response to mitogen-activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study.
Henter JI; Kvedaraite E; Martín Muñoz D; Cheng Munthe-Kaas M; Zeller B; Nystad TA; Björklund C; Donnér I; Lourda M; Zetterberg H; Blennow K; Herold N; Gavhed D; von Bahr Greenwood T
Br J Haematol; 2022 Jan; 196(1):248-254. PubMed ID: 34435355
[No Abstract] [Full Text] [Related]
4. From mutation to management: Advancing Langerhans cell histiocytosis treatment through combination therapies.
Diamond A
Br J Haematol; 2024 May; 204(5):1588-1589. PubMed ID: 38606542
[TBL] [Abstract][Full Text] [Related]
5. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
[TBL] [Abstract][Full Text] [Related]
6. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
7. High levels of plasma interleukin-17A are associated with severe neurological sequelae in Langerhans cell histiocytosis.
Ismail MB; Åkefeldt SO; Lourda M; Gavhed D; Aricò M; Henter JI; Delprat C; Valentin H
Cytokine; 2020 Feb; 126():154877. PubMed ID: 31629106
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
[TBL] [Abstract][Full Text] [Related]
9. A circulating subset of BRAF
Poch R; Le Louet S; Hélias-Rodzewicz Z; Hachem N; Plat G; Barkaoui MA; Lapillonne H; Delhommeau F; Emile JF; Donadieu J; Héritier S
Br J Haematol; 2021 Aug; 194(4):745-749. PubMed ID: 34312844
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosis.
Gavhed D; Akefeldt SO; Osterlundh G; Laurencikas E; Hjorth L; Blennow K; Rosengren L; Henter JI
Pediatr Blood Cancer; 2009 Dec; 53(7):1264-70. PubMed ID: 19688833
[TBL] [Abstract][Full Text] [Related]
11. Circulating cell-free BRAF
Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of oncogenic mutations in pulmonary Langerhans cell histiocytosis.
Brown NA; Elenitoba-Johnson KSJ
Curr Opin Pulm Med; 2018 May; 24(3):281-286. PubMed ID: 29470255
[TBL] [Abstract][Full Text] [Related]
13. Pattern and course of neurodegeneration in Langerhans cell histiocytosis.
Wnorowski M; Prosch H; Prayer D; Janssen G; Gadner H; Grois N
J Pediatr; 2008 Jul; 153(1):127-32. PubMed ID: 18571550
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction.
Eckstein O; McAtee CL; Greenberg J; Kumar A; Fein-Levy C; Smith T; Tran B; McClain KL
Pediatr Hematol Oncol; 2018; 35(7-8):427-433. PubMed ID: 30596314
[TBL] [Abstract][Full Text] [Related]
15. Co-existence of Langerhans cell histiocytosis and reticulohistiocytosis with initial presentation of skull lesions: A case report.
Shen WC; Chang Liao NF; Lin TY; Wu PY
J Cutan Pathol; 2019 Jan; 46(1):62-66. PubMed ID: 30251332
[TBL] [Abstract][Full Text] [Related]
16. Langerhans cell histiocytosis.
Rodriguez-Galindo C; Allen CE
Blood; 2020 Apr; 135(16):1319-1331. PubMed ID: 32106306
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and treatment of Langerhans cell histiocytosis.
Rodriguez-Galindo C
Acta Paediatr; 2021 Nov; 110(11):2892-2902. PubMed ID: 34192374
[TBL] [Abstract][Full Text] [Related]
18. Genomic Alterations in Langerhans Cell Histiocytosis.
Rollins BJ
Hematol Oncol Clin North Am; 2015 Oct; 29(5):839-51. PubMed ID: 26461146
[TBL] [Abstract][Full Text] [Related]
19. New somatic BRAF splicing mutation in Langerhans cell histiocytosis.
Héritier S; Hélias-Rodzewicz Z; Chakraborty R; Sengal AG; Bellanné-Chantelot C; Thomas C; Moreau A; Fraitag S; Allen CE; Donadieu J; Emile JF
Mol Cancer; 2017 Jul; 16(1):115. PubMed ID: 28679432
[TBL] [Abstract][Full Text] [Related]
20. [Pathophysiology and treatment of adult Langerhans cell histiocytosis].
Tojo A; Kobayashi M
Rinsho Ketsueki; 2020; 61(9):1028-1034. PubMed ID: 33162496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
